AACAP lists Strattera as a first-line therapy option for ADHD
Added
May-2004
The American Academy of Child and Adolescent Psychiatry (AACAP), the leading
professional organization for child and adolescent psychiatry, today issued
guidelines that highlight the importance of accurate diagnosis and appropriate
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
The guidelines include new recommendations for treatment in which Strattera®
(atomoxetine HCl) is a first-line therapy option for ADHD. This marks the
first time AACAP has listed a nonstimulant as a first-line therapy option
for ADHD
Strattera works differently than stimulants as it is a norephinephrine reuptake
inhibitor. It is the only medication indicated specifically for the treatment
of ADHD in children, adolescents and adults. Strattera provides full-day symptom
control without insomnia in most children and adolescents ...
FULL
STORY